Extendicare (TSE:EXE – Free Report) had its target price upped by TD Securities from C$9.00 to C$9.50 in a research report report published on Wednesday morning, BayStreet.CA reports. They currently have a hold rating on the stock.
Separately, Royal Bank of Canada lifted their target price on shares of Extendicare from C$8.50 to C$9.50 in a research report on Monday, August 19th.
Get Our Latest Analysis on Extendicare
Extendicare Stock Down 0.5 %
Extendicare (TSE:EXE – Get Free Report) last posted its earnings results on Monday, August 12th. The company reported C$0.29 EPS for the quarter. Extendicare had a return on equity of 60.00% and a net margin of 4.28%. The firm had revenue of C$348.48 million during the quarter, compared to the consensus estimate of C$360.20 million.
Extendicare Announces Dividend
The business also recently announced a monthly dividend, which will be paid on Monday, September 16th. Shareholders of record on Friday, August 30th will be issued a dividend of $0.04 per share. This represents a $0.48 annualized dividend and a yield of 5.43%. The ex-dividend date of this dividend is Friday, August 30th. Extendicare’s payout ratio is presently 70.59%.
Extendicare Company Profile
Extendicare Inc, through its subsidiaries, provides care and services for seniors in Canada. The company offers long term care (LTC) services; and home health care services, such as nursing care, occupational, physical and speech therapy, and assistance with daily activities, as well as management, consulting, and other services to third parties.
Featured Stories
- Five stocks we like better than Extendicare
- How to Invest in Small Cap StocksĀ
- Is Merck Stock Undervalued After Its Colossal Earnings Growth?
- Breakout Stocks: What They Are and How to Identify Them
- Top 5 ETFs for Every Investor: From Semiconductors to Defense
- What is a SEC Filing?
- Blade Air Mobility: This Under-the-Radar Stock Could Double Soon
Receive News & Ratings for Extendicare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Extendicare and related companies with MarketBeat.com's FREE daily email newsletter.